Definium Therapeutics (DFTX) Prepaid Assets (2020 - 2026)
Definium Therapeutics' (DFTX) quarterly Prepaid Assets came in at $7.1 million in Q1 2026, down 22.88% year-on-year from $9.3 million in Q1 2025, and down 7.58% on a QoQ basis from $7.7 million in Q4 2025.
Definium Therapeutics (DFTX) Prepaid Assets (2020 - 2026) Analysis & Trends
Definium Therapeutics (DFTX) has 7 years of Prepaid Assets data on file, last reported at $7.1 million in Q1 2026.
- On a quarterly basis, Prepaid Assets fell 22.88% year-over-year to $7.1 million in Q1 2026; TTM through Mar 2026 was $7.1 million, a 22.88% decrease from a year earlier, with the FY2025 full-year figure at $7.7 million, down 1.93% from the prior year.
- Prepaid Assets for Q1 2026 stood at $7.1 million, down from $7.7 million in the prior quarter.
- Over the last five years, Prepaid Assets for DFTX reached as high as $9.3 million in Q1 2025 and fell as low as $1.8 million in Q3 2022.
- Historically, Prepaid Assets has averaged $4.8 million across 5 years, with a median of $4.1 million in 2024.
- Across the five-year window, Prepaid Assets surged 194.97% in 2025 and dropped 22.88% in 2026, its largest moves.
- Year by year, Prepaid Assets stood at $3.9 million in 2022, then advanced by 6.52% to $4.2 million in 2023, then jumped by 89.04% to $7.9 million in 2024, then fell by 1.93% to $7.7 million in 2025, then decreased by 7.58% to $7.1 million in 2026.
- Per Business Quant data, the three most recent Prepaid Assets figures were $7.1 million in Q1 2026, $7.7 million in Q4 2025, and $6.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - |
| 2 | Nanobiotix | 1,908.96 Bn | 1,908.90 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 474.03 Bn | 469.24 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn |
| 10 | Definium Therapeutics | 4.67 Bn | 4.67 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.14 Mn |
| Dec 31, 2025 | 7.73 Mn |
| Sep 30, 2025 | 6.78 Mn |
| Jun 30, 2025 | 6.14 Mn |
| Mar 31, 2025 | 9.26 Mn |
| Dec 31, 2024 | 7.88 Mn |
| Sep 30, 2024 | 4.07 Mn |
| Jun 30, 2024 | 4.56 Mn |
| Mar 31, 2024 | 3.14 Mn |
| Dec 31, 2023 | 4.17 Mn |
| Sep 30, 2023 | 2.39 Mn |
| Jun 30, 2023 | 2.90 Mn |
| Mar 31, 2023 | 3.00 Mn |
| Dec 31, 2022 | 3.91 Mn |
| Sep 30, 2022 | 1.83 Mn |
| Jun 30, 2022 | 3.17 Mn |
| Mar 31, 2022 | 2.76 Mn |
| Dec 31, 2021 | 3.68 Mn |
| Dec 31, 2020 | 1.43 Mn |